Company: TELO
Filing Date: 2025-06-18
Form Type: 8-K
Source: 0001641172-25-015522
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-06-18
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

On
June 18, 2025, Telomir Pharmaceuticals, Inc. (Nasdaq: TELO), a preclinical-stage biotechnology company focused on reversing biological
aging and age-related diseases, announced positive new preclinical data demonstrating the cellular protective activity of its lead candidate,
Telomir-1, in human progeria cell lines.

Progeria,
or Hutchinson-Gilford Progeria Syndrome (HGPS), is an ultra-rare pediatric disorder caused by a mutation in the LMNA

The
Company evaluated Telomir-1 in cells taken directly from a child with HGPS. These cells were obtained from The Progeria Research Foundation
( www. progeriaresearch. org

Key
findings include:

  Telomir-1                                                                                                                             
  significantly increased cell viability, both under basal conditions and even in the presence of toxic levels of iron and copper.      
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Reactive                                                                                                                              
  Calcium                                                                                                                               

Telomir-1
is designed to regulate intracellular metal ions, reduce oxidative stress, restore mitochondrial function, extend telomere length, reverse
muscle loss, and reset age-associated DNA methylation patterns - biological pathways that play central roles in Progeria and other
degenerative conditions.

The
results build on prior studies in zebrafish and C. elegans

Telomir
Pharmaceuticals is finalizing IND-enabling studies and intends to engage with the U. S. Food and Drug Administration (FDA) to explore
regulatory pathways, including the potential for orphan drug designation. The Company is evaluating multiple rare disease indications
for initial clinical development.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                     TELOMIR                                       
  Dated:             By:                        /s/                
                     Name:                      Erez               
                     Title:                     Chief